Show simple item record

dc.contributor.authorChacra, Antonio R. [UNIFESP]
dc.date.accessioned2016-01-24T14:37:16Z
dc.date.available2016-01-24T14:37:16Z
dc.date.issued2014-05-01
dc.identifierhttp://dx.doi.org/10.1097/MJT.0b013e318235f1bb
dc.identifier.citationAmerican Journal of Therapeutics. Philadelphia: Lippincott Williams & Wilkins, v. 21, n. 3, p. 198-210, 2014.
dc.identifier.issn1075-2765
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/37745
dc.description.abstractOver the last 40 years, metformin has revolutionized the treatment of type-2 diabetes worldwide and is still the most influential oral antidiabetic drug today. International guidelines now recommend that patients with type-2 diabetes are started on metformin therapy as soon as they are diagnosed, as it has been shown to improve long-term clinical outcomes compared with initial management with diet alone, without increasing the risk of developing hypoglycemia or weight gain. the older, immediate-release formulation of metformin does have some limitations, with incidence of gastrointestinal adverse effects restricting the dose in some patients, forming a barrier to treatment adherence, and subsequent glycemic control. However, the second-generation extended-release formulation (met XR) has the potential to overcome these challenges. in this review, we provide an overview of the evidence supporting the use of metformin as the first-line gold standard for type-2 diabetes management and the expansion of its potential roles for the future. We also consider the advantages of met XR, in terms of its tolerability and convenient dose regimen, and review therapeutic options for when disease progression inevitably leads to inadequate control with monotherapy. These therapy options include the synergistic potential of combination strategies with met XR and dipeptidyl peptidase 4 inhibitors, a combination that has also been indicated for early-stage use (at diagnosis) as a potential method for preserving -cell function.en
dc.description.sponsorshipAstraZeneca
dc.description.sponsorshipBristol-Myers Squibb
dc.format.extent198-210
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofAmerican Journal of Therapeutics
dc.rightsAcesso restrito
dc.subjectmetforminen
dc.subjecttype 2 diabetesen
dc.subjecttreatmenten
dc.subjectimmediate releaseen
dc.subjectextended releaseen
dc.titleEvolving Metformin Treatment Strategies in Type-2 Diabetes: From Immediate-Release Metformin Monotherapy to Extended- Release Combination Therapyen
dc.typeResenha
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.description.affiliationUniversidade Federal de São Paulo, Ctr Diabet, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Ctr Diabet, São Paulo, Brazil
dc.identifier.doi10.1097/MJT.0b013e318235f1bb
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000335977800020


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record